An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of DCLL9718S in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination with Azacitidine in Patients with Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
The goal of this clinical research study is to learn about the safety and tolerability of DCLL9718S alone or in combination with azacitidine when given to patients with acute myeloid leukemia (AML). This is the first study using DCLL9718S in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Azacitidine, DCLL9718S
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Genentech, Inc.
IRB Review and Approval Date: 08/14/2018
Recruitment Status: Open
Projected Accrual: 30-110
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: